A Potential Mesothelioma Cancer Treatment Drug Shows Promise for the Shrinking of Tumors

The mesothelioma cancer treatment drug was distributed to thirteen patients, each suffering from advanced solid tumors. Initially distributed to these terminally ill patients for the purposes of identifying what constitutes a suitable dosage, both patients and doctors were surprised to learn that the drug caused tumors to shrink in a number of the patients under observation. The people receiving the drug were so impressed with the mesothelioma cancer treatment that at the end of the one-week trial they asked to be kept on the drug.

Asbestos is the only known cause of mesothelioma, a deadly cancer that occurs primarily in the lining of the abdomen and lungs. The disease usually manifests itself at least fifteen years after the initial exposure to Asbestos. Asbestos can cause mesothelioma even if the exposure occurs for only a short period. Asbestos fibers are microscopic and exposure can occur without a worker even knowing it. Mesothelioma occurs not only in people working directly with Asbestos products but also in bystanders and family members exposed to Asbestos dust.